Healios to fast-track pluripotent stem cell therapy

Healios K.K. to bring its novel regenerative pluripotent stem cell treatments to market through accelerated Japanese approvals process.

Stem cell pioneers Healios KK will use the upcoming JP Morgan Healthcare Conference and Biotech Showcase in San Francisco CA to highlight its innovative approach to regenerative medication.

The company, which is Japan’s leading clinical stage biotech company, is focused on harnessing the power of stem cells for regenerative therapies which include organ regeneration [1].

Longevity.Technology: Healios is using cutting edge stem cell technology to address a range of serious conditions. Time is of the essence and they clearly believe that getting these treatments to market as quickly as possible has the potential to accelerate commercialisation.

The company’s CFO Richard Kincaid will use the biotech conference, being held between the 13th and 16th January, to present the company’s strategy in regenerative medicine. The therapy combines near-term and potentially accelerated commercialisation of Somatic Stem Cell (SSC) based treatments with the development of next generation therapies thanks to its induced Pluripotent Stem Cell technology platform.

Healios is currently in a pivotal second/third stage trial in Japan in Ischemia stroke which offers the potential for effective treatment.

In addition, it is also in the middle of a Phase 2 trial in acute respiratory distress syndrome (ARDS) in Japan and hopes to deliver the world’s first approved therapeutic drug.

Assuming these studies are completed successfully, Healios intends to accelerate along the path to approval and commercialisation thanks to Japan’s highly favourable regulatory framework, the Conditional and Time Limited Authorisation System, or SAKIGAKE in Japanese [2].

The strategy was conceived by the ministry of health to accelerate the development of innovative medicines and, where possible, accelerate the practical application of off label life saving medications to the wider audience.

Alongside this, Healios is developing a proprietary gene modified iPSC Platform of non-immunogenic, off-the-shelf (allogenic) ‘Universal Donor Cells’ for applications in next-generation therapies in ophthalmology, organ regeneration, and immuno-oncology.

This includes the development of iPSC derived gene-modified natural killer cells, which can offer long-lasting effects while still avoiding the need for immunosuppressive drug treatment.

[1] https://prn.to/35yAQ1e

[2] https://bit.ly/39UAcym

Image credit: Healios

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...